Dear Mr. President, dear Q,

I am not sure, if you are aware of this knowledge:

HCQ has been identified as one of the drugs that cause severe damage, for example to erythrocytes, in people with hereditary glucose-6-phosphate dehydrogenase (G6PD) deficiency. As an effect of HCQ application in case of G6DP deficiency a strong hemolysis is seen after 1-2 days.

The erythrocyte debris causes microemboli and damages sensitive organs such as kidneys and brain. In addition, erythrocytes are then missing as oxygen carriers.

1-2 days after the start of such treatment, a very severe clinical picture develops with weakness, dizziness, shortness of breath and signs of organ damage.

This can end in death if the toxic medication is not stopped immediately.

If the medication is discontinued, the shortness of breath improves spontaneously thanks to a rapid normalisation of the blood count. Above all, the control of kidney function remains important.

Hardly anyone seems to be aware that e.g. in sub-Saharan Africa, a hereditary G6PD deficiency is widespread (20-30% of the population).

But also in other countries where malaria was or still is endemic, there is a high prevalence of G6PD deficiency. G6PD deficiency must also be considered in migrant families, e.g. in Chicago, New York and elsewhere. In these populations, triggered by already questionable SARS-CoV-2 test results, treatment or prevention with dangerous drugs like HCQ alone can kill many people.

------

It would be wise to differenciate the use of HCQ, which is one of the best solutions for Covid-19, but should be used very cautious on black and asian people. A G6PD-Gen-Test should be done before using HCQ.

Best regards,

J.

Source: (in German)

https://www.wodarg.com/2020/04/26/warnung-zu-hydroxychloroquin-bei-patienten-mitg6pd-mangel/